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receptor 1 and phospho-signal transducer and
activator of transcription 3 is associated with poor
prognosis in rituximab-treated diffuse large B-cell
lymphomas
Jin Ho Paik1,4, Soo Jeong Nam1,2, Tae Min Kim3, Dae Seog Heo3, Chul-Woo Kim1,2 and Yoon Kyung Jeon1,2*Abstract
Background: Sphingosine-1-phosphate receptor-1 (S1PR1) and signal transducer and activator of transcription-3
(STAT3) play important roles in immune responses with potential oncogenic roles.
Methods: We analyzed S1PR1/STAT3 pathway activation using immunohistochemistry in rituximab-treated diffuse
large B-cell lymphomas (DLBCL; N = 103).
Results: Nuclear expression of pSTAT3 (but not S1PR1) was associated with non-GCB phenotype (p = 0.010). In
univariate survival analysis, S1PR1 expression (S1PR1+) was a poor prognostic factor in total DLBCLs (p = 0.018), as well
as in nodal (p = 0.041), high-stage (III, IV) (p = 0.002), and high-international prognostic index (IPI; 3–5) (p = 0.014)
subgroups, while nuclear expression of pSTAT3 (pSTAT3+) was associated with poor prognosis in the low-stage (I, II)
subgroup (p = 0.022). The S1PR1/pSTAT3 risk-categories, containing high-risk (S1PR1+), intermediate-risk (S1PR1-/
pSTAT3+), and low-risk (S1PR1-/pSTAT3-), predicted overall survival (p = 0.010). This prognostication tended to be valid
in each stage (p = 0.059 in low-stage; p = 0.006 in high-stage) and each IPI subgroups (p = 0.055 [low-IPI]; p = 0.034
[high-IPI]). S1PR1 alone and S1PR1/pSTAT3 risk-category were significant independent prognostic indicators in
multivariate analyses incorporating IPI and B symptoms (S1PR1 [p = 0.005; HR = 3.0]; S1PR1/pSTAT3 risk-category
[p = 0.019: overall; p = 0.024, HR = 2.7 for S1PR1-/pSTAT3+ vs. S1PR1+; p = 0.021, HR = 3.8 for S1PR1-/pSTAT3- vs. S1PR1+]).
Conclusions: Therefore, S1PR1 and S1PR1/pSTAT3 risk-category may contribute to risk stratification in rituximab-treated
DLBCLs, and S1PR1 and STAT3 might be therapeutic targets for DLBCL.
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Diffuse large B-cell lymphoma (DLBCL) is a biologically
and clinically heterogeneous entity that accounts for
30-50% of non-Hodgkin lymphomas, depending on geo-
graphical area [1,2]. Germinal center B-cell-like (GCB)
and activated B-cell-like (ABC)/non-GCB subgroups were
previously identified as two distinct subgroups of DLBCL* Correspondence: junarplus@chol.com
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unless otherwise stated.that showed differentially activated signaling pathways
[1,3-6]. Typically, the NF-κB pathway is constitutively
activated in ABC-like DLBCLs and cooperates with the
STAT3 pathway to promote cell survival [7-9], while de-
pendency on the PI3K/Akt pathway has been demonstrated
in GCB-type DLBCL [10]. Recently, high-throughput
techniques have revealed more complex features of genetic
alterations and identified novel therapeutic pathways in
DLBCL [9,11,12]. One of the promising candidate pathways
for targeted therapy in DLBCL is the STAT3 pathway [13].
Unlike inflammatory conditions with transient STAT3
activation, STAT3 is aberrantly and constitutively activated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[14]. Activated STAT3, i.e., phospho-STAT3 (pSTAT3), is
transported into the nucleus, functioning as a transcrip-
tion factor for various genes involving cellular apoptosis,
proliferation, and survival [15]. In lymphomas, the expres-
sion and activation of STAT3 have previously been investi-
gated in human lymphoma tissues and cell lines [16-18].
The nuclear expression of STAT3 or pSTAT3 alone, as
detected by immunohistochemistry, was shown to be a
poor prognostic factor in all DLBCL patients, including
the GCB and non-GCB/ABC subgroups [16,17].
S1PR1 is a member of the G-protein-coupled receptor
for sphingosine-1-phosphate (S1P), a chemokine mediat-
ing immune cell migration [19,20]. S1P is produced
intracellularly by sphingosine kinase (SPHK) 1/2; it is re-
leased from the cells and then binds to the S1P receptors
(S1PR1-S1PR5) of target cells in an autocrine and/or
paracrine manner [20,21]. S1PR1 transduces intracellular
signals, leading to various biologic effects, including cell
proliferation, survival and migration via the ERK, Akt,
and Rac pathways, respectively. Recently, it has been
reported that S1PR1 is also transcribed by pSTAT3, and
enhanced S1PR1 subsequently and reciprocally activates
STAT3, thus building a positive feedback loop that in-
volves the S1PR1/pSTAT3 pathway, which is important
for consistent STAT3 activation in mouse and human
solid tumors and tumor-associated myeloid cells [22].
At present, only a few studies on S1PR1 in malignant
lymphoma are available. Hodgkin lymphoma and mantle
cell lymphoma showed S1PR1 expression in cell lines or
tissues, suggesting potential biologic roles for S1PR1 in this
context [23,24]. Furthermore, co-activation of S1PR1 and
STAT3 was observed in ABC-DLBCL cells and tissues, and
S1PR1 was suggested as a potential target for blocking
STAT3 activation [18]. However, there have been no inte-
grated studies on the clinicopathologic and prognostic im-
plications of S1PR1 and STAT3 activation in DLBCL
patients. We hypothesized that S1PR1, STAT3, and/or the
co-activation of S1PR1/STAT3 pathway might be useful
prognostic markers in DLBCL. In this study, we com-
prehensively investigated the expression of S1PR1 and
pSTAT3 and analyzed their correlation with clinico-




A total of 103 patients, who were diagnosed with
DLBCL at Seoul National University Hospital from
2001 to 2010 and treated with rituximab-based chemo-
therapy, were enrolled. The patients’ histologic slides
and clinical medical records were reviewed by two expe-
rienced hemato-pathologists (J.H.P. and Y.K.J.) and
hemato-oncologists (T.M.K. and D.S.H), respectively.The follow-up duration ranged from 0 to 105 months
(median, 22 months). In total, 32 patients (31%) had died
at the time of analysis. The Institutional Review Board of
Seoul National University Hospital approved this study
(1012-053-344). Informed consent for participation in the
study was waivered by the Institutional Review Board of
Seoul National University Hospital on the basis that this
study was a retrospective study using archived material,
and did not increase risk to the patients.
Immunohistochemistry and classification of germinal
center B-cell (GCB) and non-GCB phenotype DLBCL
For immunohistochemistry (IHC), 2-mm-diameter cores
were taken from representative formalin-fixed paraffin-
embedded (FFPE) tissue blocks of patients, and tissue
microarrays (TMAs) were manufactured as previously
described [25]. DLBCL was classified into GCB and
non-GCB phenotypes on the basis of the Hans and Choi
classifications with CD10, bcl-6, MUM1, GCET1 and
FoxP1 immunostaining, as previously described [3,4,25].
IHC for S1PR1 and pSTAT3 were performed using the
Leica BOND-MAX automated immunostainer (Leica
Microsystems, Wetzlar, Germany) and the following anti-
bodies: S1PR1 (rabbit polyclonal, EDG-1 (H60), Santa
Cruz, Dallas, TX, USA) and pSTAT3 (Y705) (D3A7, rabbit
monoclonal, Cell Signaling, Danvers, MA, USA). Consen-
sus interpretation of IHC was performed by two hemato-
pathologists (J.H.P. and Y.K.J.) using multi-head light
microscope (BX43, Olympus, Tokyo, Japan) for one core
per each case.
Of the 103 DLBCLs, immunophenotyping was successful
in 99 cases. Of them, 8% (8/99) were discordant between
the Hans and Choi classifications. Specifically, 5 cases were
classified as GCB by Hans but ABC by Choi, whereas 3
cases were classified as non-GCB by Hans but GCB by
Choi. The remaining 91 cases were classified concordantly,
with 32 classified as GCB and 59 classified as non-GCB/
ABC. Because no clinicopathologic differences were ob-
served between subtypes according to the Hans or Choi
classification and S1PR1/pSTAT3 expression, in this study,
further analysis was performed using the Hans classification.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 (SPSS
Inc., Chicago, IL, USA). Cross-table analysis was performed
using a two-sided Pearson’s χ2-test. Survival analysis was
performed using Kaplan-Meier (univariate) and Cox pro-
portional hazard models (multivariate) for overall survival.
P-values <0.05 were considered statistically significant.
Results
Clinical features of rituximab-treated DLBCL
As shown in Table 1, the median age of patients was
61 years and ranged from 14 to 79 years. Patients with
Table 1 Clinicopathologic features of rituximab-treated
diffuse large B cell lymphoma patients (N = 103)
Variables Total n (%) GCB* n (%) Non-GCB* n (%)
Age, years
Mean (range) 57.7 (14–79) 60.5 (23–79) 56.2 (14–78)
<60 50 (49%) 13 (35%) 35 (56%)
≥60 53 (51%) 24 (65%) 27 (44%)
Sex
Male 61 (59%) 23 (62%) 36 (58%)
Female 42 (41%) 14 (38%) 26 (42%)
Primary site
Nodal 37 (36%) 14 (38%) 21 (34%)
Extranodal 66 (64%) 23 (62%) 41 (66%)
Ann Arbor stage
I, II 47 (46%) 19 (51%) 27 (44%)
III, IV 56 (54%) 18 (49%) 35 (56%)
IPI group†
Low (0–2) 60 (63%) 24 (65%) 33 (60%)
High (3–5) 36 (37%) 13 (35%) 22 (40%)
B symptoms†
Absent 74 (76%) 31 (84%) 43 (72%)
Present 24 (24%) 6 (16%) 17 (28%)
ECOG PS†
0, 1 86 (84%) 34 (92%) 49 (80%)
≥2 16 (16%) 3 (8%) 12 (20%)
LDH†
Normal 43 (45%) 14 (39%) 26 (46%)
Elevated 53 (55%) 22 (61%) 30 (54%)
BM involvement†
Absent 85 (86%) 34 (92%) 48 (83%)
Present 14 (14%) 3 (8%) 10 (17%)
Number of
extranodal sites
0, 1 75 (73%) 26 (70%) 46 (74%)
≥2 28 (27%) 11 (30%) 16 (26%)
EBER†
Negative 95 (94%) 37 (100%) 55 (90%)
Positive 6 (6%) 0 (0%) 6 (10%)
Treatment
Rituximab + CHOP 97 (94%) 37 (100%) 57 (92%)
Rituximab + others 6 (6%) 0 (%) 5 (8%)
GCB, germinal center B-cell like; IPI, international prognostic index; ECOG PS,
Eastern Cooperative Oncology Group performance status; LDH, lactate
dehydrogenase; BM, bone marrow; EBER, EBV-encoded RNA; CHOP,
cyclophosphamide, doxorubicin, vincristine, prednisolone. *GCB and
non-GCB phenotypes were classified using Hans classification with four
unclassifiable cases. †The number excludes missing values.
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64/99), and low international prognostic index (IPI; score
0–2; 62%, 57/92) were more frequent. All patients were
treated with rituximab-containing regimens. In 94%
(94/99), the patients were treated with rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone
(R-CHOP). There were no significant differences in clin-
ical variables between the GCB and non-GCB phenotypes.
Expression patterns of S1PR1 and pSTAT3 in DLBCLs
Consistent with a previous report [24], S1PR1 was
expressed in the cytoplasm of reactive mantle zone
B-cells and endothelial cells in non-neoplastic tonsils
(Figure 1A). In DLBCLs, S1PR1 was stained in the cyto-
plasm of tumor cells with variable intensities and pro-
portions (Figure 1B-D). Cases showing S1PR1 staining
with an intensity similar to or stronger than reactive
mantle B-cells in more than 30% of tumor cells were
interpreted as being positive for S1PR1 expression.
pSTAT3 was stained in the histiocytes and endothelial
cells of non-neoplastic tonsils (Figure 1E). In DLBCLs,
pSTAT3 was stained in the cytoplasm or in both the
cytoplasm and nucleus (Figure 1F-H). Considering that
the active form of STAT3 (pSTAT3) is transported into
the nucleus to be functional [14], cases that exhibited
nuclear staining in more than 30% of tumor cells were
interpreted as being positive for pSTAT3 expression.
Using these criteria, S1PR1 expression was positive in
40% (41/103) and pSTAT3 expression was positive in
59% (61/103) of DLBCL (Table 2).
Relationships between S1PR1/pSTAT3 expression and
clinicopathologic variables
The correlations between S1PR1/pSTAT3 expression and
clinicopathologic features are summarized in Table 2.
Briefly, the expression of S1PR1 and pSTAT3 was more
frequently observed in DLBCLs, primarily occurring in
extranodal sites (p = 0.047 for S1PR1; p = 0.013 for
pSTAT3) and upper aerodigestive tract (UAT) including
nasal cavity, nasopharynx, oral cavity, oropharynx, and
hypopharynx (p = 0.010 for S1PR1; p = 0.009 for pSTAT3).
Bone marrow involvement was more common in patients
with pSTAT3-positive DLBCLs (p = 0.032). Otherwise, no
significant relationships were observed between the
expression of S1PR1/pSTAT3 and other clinical variables.
pSTAT3 expression was much more frequently observed
in non-GCB cases than in GCB cases (p = 0.010), while
S1PR1 expression was not significantly different between
these groups.
Univariate survival analysis with conventional
clinicopathologic variables and S1PR1/pSTAT3
As shown in Table 3, univariate survival analysis for
overall survival was performed in a total of 103 cases of
Figure 1 S1PR1 and pSTAT3 immunostaining patterns. (A) Reactive mantle zone B-cells and endothelial cells express S1PR1. S1PR1
immunostaining was considered to be negative for cases with no staining (B) or weaker staining than mantle zone B-cells (C) and positive for
cases with similar to or stronger staining than mantle zone B-cells (D). (E) Histiocytes and endothelial cells are stained for pSTAT3. pSTAT3
immunostaining was considered negative for cases with no staining (F) or cytoplasmic staining (G) and positive for the cases with nuclear
staining in tumor cells (H).
Paik et al. BMC Cancer 2014, 14:911 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/911DLBCL, as well as in the following subgroups: nodal vs.
extranodal, low stage (I, II) vs. high stage (III, IV), low
IPI (0–2) vs. high IPI (3–5), and GCB vs. non-GCB. In
the total cohort, high stage and high IPI were significant
poor prognostic factors (p = 0.016 for stage; p = 0.009
for IPI; Figure 2A and B), along with old age (>60 y),
presence of B symptoms, and high LDH level (Table 3).
The expression of S1PR1 was a significant poor prog-
nostic factor (p = 0.018; Figure 2C), while pSTAT3 expres-
sion was not. However, in the subgroup analyses (Table 3),
S1PR1 was a significant poor prognostic factor in the
nodal (p = 0.041), high stage (p = 0.002), and high IPIsubgroups (p = 0.014). In contrast, pSTAT3 expression
was associated with shorter overall survival in patients
with low stage (p = 0.022) and low IPI group (p = 0.067).
Survival analysis with risk stratification model using
S1PR1/pSTAT3
Given the integrated role of S1PR1 and pSTAT3 in
oncogenesis [22] and the above observation that sug-
gested a possible complementary effect of S1PR1 and
pSTAT3 on the prognosis of DLBCLs, we made a new
immunohistochemical variable combining S1PR1 and
pSTAT3 expression, specifically, a S1PR1/pSTAT3 risk
Table 2 Correlation between S1PR1/pSTAT3 expression and clinicopathologic variables
variables S1PR1 pSTAT3
Negative Positive Total P* Negative Positive Total P*
Age, years
Mean (range)
<60 30 (48%) 20 (49%) 50 (49%) 0.969 21 (50%) 29 (48%) 50 (49%) 0.806
≥60 32 (52%) 21 (51%) 53 (51%) 21 (50%) 32 (52%) 53 (51%)
Sex
Male 34 (55%) 29 (67%) 61 (59%) 0.265 28 (67%) 33 (54%) 61 (59%) 0.202
Female 28 (45%) 14 (33%) 42 (41%) 14 (33%) 28 (46%) 42 (41%)
Primary nodal disease
Nodal 27 (44%) 10 (24%) 37 (36%) 0.047† 21 (50%) 16 (26%) 37 (36%) 0.013†
Extranodal 35 (56%) 31 (76%) 66 (64%) 21 (50%) 45 (74%) 66 (64%)
Primary UAT disease
Non-UAT 55 (89%) 28 (68%) 83 (81%) 0.010† 39 (93%) 44 (72%) 83 (81%) 0.009†
UAT 7 (11%) 13 (32%) 20 (19%) 3 (7%) 17 (28%) 20 (19%)
Ann Arbor stage
I, II 26 (42%) 21 (51%) 47 (46%) 0.354 18 (43%) 29 (48%) 47 (46%) 0.639
III, IV 36 (58%) 20 (49%) 56 (54%) 24 (57%) 32 (52%) 56 (54%)
IPI group‡
Low (0–2) 36 (61%) 24 (65%) 60 (63%) 0.705 23 (59%) 37 (65%) 60 (63%) 0.555
High (3–5) 23 (39%) 13 (35%) 36 (37%) 16 (41%) 20 (35%) 36 (37%)
B symptoms‡
Absent 46 (76%) 31 (78%) 77 (76%) 0.809 36 (86%) 41 (69%) 77 (76%) 0.059
Present 15 (24%) 9 (22%) 24 (24%) 6 (14%) 18 (31%) 24 (24%)
ECOG PS‡
0, 1 54 (87%) 32 (80%) 86 (84%) 0.336 36 (86%) 50 (83%) 86 (84%) 0.745
≥2 8 (13%) 8 (20%) 16 (16%) 6 (14%) 10 (17%) 16 (16%)
LDH‡
Normal 25 (43%) 18 (47%) 43 (45%) 0.681 16 (42%) 27 (47%) 43 (45%) 0.668
Elevated 33 (57%) 20 (53%) 53 (55%) 22 (58%) 31 (53%) 53 (55%)
BM involvement‡
Absent 56 (90%) 29 (78%) 85 (86%) 0.099 38 (95%) 47 (80%) 85 (86%) 0.032†
Present 6 (10%) 8 (22%) 14 (14%) 2 (5%) 12 (20%) 14 (14%)
Number of extranodal sites
0, 1 45 (73%) 30 (73%) 75 (73%) 0.947 30 (71%) 45 (74%) 75 (73%) 0.793
≥2 17 (27%) 11 (27%) 28 (27%) 12 (29%) 16 (26%) 28 (27%)
EBER‡
Negative 58 (94%) 37 (95%) 95 (94%) 0.784 39 (93%) 56 (95%) 95 (94%) 0.666
Positive 4 (6%) 2 (5%) 6 (6%) 3 (7%) 3 (5%) 6 (6%)
Hans classification‡
GCB 24 (40%) 13 (33%) 37 (37%) 0.503 21 (53%) 16 (27%) 37 (37%) 0.010†
Non-GCB 36 (60%) 26 (67%) 62 (63%) 19 (47%) 43 (73%) 62 (63%)
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Table 2 Correlation between S1PR1/pSTAT3 expression and clinicopathologic variables (Continued)
pSTAT3 nuclear expression
Negative 28 (45%) 14 (34%) 42 (41%) 0.265 - - - -
Positive 34 (55%) 27 (66%) 61 (59%) - - -
Total 62 (100%) 41 (100%) 103 (100%) 42 (100%) 61 (100%) 103 (100%)
DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell like; ABC, activated B-cell like; IPI, international prognostic index; ECOG PS, Eastern Cooperative
Oncology Group performance status; LDH, lactate dehydrogenase; BM, bone marrow; EBER, EBV-encoded RNA; UAT, upper aerodigestive tract. *P values were
calculated using Pearson’s chi-square test. †indicates P values are less than 0.05. ‡The number excludes missing values.
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useful for predicting the prognosis of DLBCL patients
who were defined as follows: 1) high risk: S1PR1+, 2)
intermediate risk: S1PR1-/pSTAT3+, and 3) low risk
group: S1PR1-/pSTAT3-. The S1PR1/pSTAT3 risk
category was a significant prognostic factor in the total
cohort of rituximab-treated DLBCL patients (N = 103)
(Figure 2D). Furthermore, this risk category tended to be
valid in low stage (p = 0.059) and high stage (p = 0.006)
subgroups, as well as in the low IPI (p = 0.055) and high
IPI subgroups (p = 0.034) (Table 3).
Multivariate survival analysis with conventional
clinicopathologic variables, S1PR1 and S1PR1/pSTAT3
risk category
To further determine the prognostic implication of
S1PR1 and pSTAT3 expression, multivariate survival ana-
lysis was performed in the total cohort of rituximab-treated
DLBCL incorporating the S1PR1 or S1PR1/pSTAT3 risk
category and conventional prognostic variables (Table 4).
In the multivariate Cox analysis with IPI, B symptoms
and S1PR1, IPI and S1PR1 were independent prognostic
factors for overall survival (p = 0.019, hazard ratio [HR] =
2.7 for IPI; p = 0.005, HR = 3.0 for S1PR1). When the
S1PR1/pSTAT3 risk category was included in the multi-
variate modeling, IPI and S1PR1/pSTAT3 risk category
were also found to be independent prognostic factors (p =
0.021, HR = 2.7 for IPI; p = 0.019 for S1PR1/pSTAT3 risk
category; p = 0.024, HR = 2.7 for high risk [S1PR1+] vs.
intermediate risk [S1PR1-/pSTAT3+]; p = 0.021, HR = 3.8
for high risk [S1PR1+] vs. low risk [S1PR1-/pSTAT3-])
(Table 4). Together, these data demonstrate that both
S1PR1 expression and S1PR1/pSTAT3 risk category are
independent prognostic predictors in DLBCL patients
treated with rituximab-based chemotherapy.
Discussion
In the present study, we demonstrated for the first time
that 1) S1PR1 is an independent prognostic factor in
rituximab-treated DLBCL patients, and 2) the S1PR1/
pSTAT3 risk category is useful for risk stratification of
DLBCL patients.
Given that S1PR1 and pSTAT3 closely co-operate
during inflammatory and immunologic processes andneoplasms, the S1PR1/pSTAT3 risk category was devel-
oped to help stratify the risk of rituximab-treated
DLBCL patients using immunohistochemistry for S1PR1
and pSTAT3. This category has prognostic value in a
stage- and IPI-independent manner. Notably, DLBCLs
with S1PR1 expression exhibited worst prognosis regard-
less of pSTAT3 expression and represented the high risk
(S1PR1+) group. Meanwhile, DLBCLs without S1PR1
expression could be divided into a low risk group
(S1PR1-/pSTAT3-), which is assumed to have an inactive
form of S1PR1 and pSTAT3, and an intermediate risk
group (S1PR1-/pSTAT3+), which might reflect pSTAT3
activation via an alternative non-S1PR1 pathway. These
data suggest that aside from the S1PR1/pSTAT3 positive
feedback loop, S1PR1- or pSTAT3-associated alternative
signaling pathways might also be involved in the biology
of DLBCL. In fact, in the present study, S1PR1 and
pSTAT3 expression did not correlate significantly with
each other (p = 0.265). Because S1P-S1PR1 signaling is
known to be associated with several important pathways,
including the mTOR pathway in T cells [26] and the Akt
pathway in non-lymphoid cells [27,28], it is possible that
S1PR1-mediated oncogenic signaling pathways other
than STAT3 might underlie the aggressive behavior of
S1PR1-positive DLBCLs. As such, the possible roles of
S1PR1 in the biology of DLBCLs via mechanisms other
than STAT3 signaling remain to be clarified.
It was previously reported that STAT3 or pSTAT3 was a
prognostic factor in DLBCLs [16,17]. In Wu’s series of 74
patients, approximately half of whom had been treated with
R-CHOP therapy, the prognosticator was not pSTAT3, but
STAT3, although the expression of these two molecules
was highly concordant [16]. STAT3 activation has previ-
ously been described as a main mechanism of ABC-
DLBCL [18], and in Huang’s series of 185 patients who
had undergone R-CHOP therapy, pSTAT3 was a signifi-
cant prognostic factor for event-free survival in ABC-
DLBCL [17]. In the present study, the nuclear expression
of pSTAT3 was much higher in the non-GCB type and
tended to be associated with shorter overall survival in
patients in the early stages or in those who had low IPIs.
However, overall, pSTAT3 expression alone was not an
independent prognostic factor in DLBCL patients treated
with rituximab and showed no prognostic significance in
Table 3 Univariate survival analysis of S1PR1/pSTAT3 expression and clinicopathologic variables for overall survival in rituximab-treated DLBCL patients (total
cohort) and clinicopathologic subgroups
Clinicopathologic variables P values in each group* by univariate analysis
Rituximab –treated DLBCL
(total cohort) (N =103)










(n = 60 )
High (3–5)





Age >60 0.019 0.027 NS (0.239) NS (0.050) NS (0.223) NS (0.141) NS (0.391) NS (0.052) 0.036
Stage (III, IV) 0.016 0.034 NS (0.145) NA NA NS (0.147) NS (0.110) NS (0.652) NS (0.008)
High IPI (3–5) 0.009 0.039 NS (0.087) <0.001 0.339 NA NA NS (0.104) 0.047
B symptoms 0.014 NS (0.576) 0.002 NS (0.481) 0.038 NS (0.836) NS (0.052) NS (0.569) 0012
High LDH 0.016 NS (0.078) NS (0.063) NS (0.083) NS (0.376) NS (0.585) NS (0.157) NS (0.955) 0.002
BM involvement NS (0.663) NS (0.790) NS (0.323) NS NS (0.711) NS (0.418) NS (0.362) NS (0.326) NS (0.478)
No. of
extranodal sites
NS (0.959) NS (0.175) NS (0.556) NS NS (0.116) NS (0.787) 0.026 NS (0.701) NS (0.662)
ECOG PS NS (0.115) NS (0.528) NS (0.147) NS (0.264) NS (0.540) NS (0.531) NS (0.679) 0.006 NS (0.756)
Hans classification NS (0.764) NS (0.118) NS (0.429) NS (0.336) NS (0.404) NS (0.789) NS (0.709) NA NA
S1PR1 0.018 0.041 NS (0.127) NS (0.880) 0.002 NS (0.347) 0.014 NS (0.092) NS (0.238)
pSTAT3 NS (0.713) NS (0.536) NS (0.996) 0.022 NS (0.267) NS (0.067) NS (0.248) NS (0.143) NS (0.256)
S1PR1/pSTAT3 risk category 0.010 NS (0.079) NS (0.254) NS (0.059) 0.006 NS (0.055) 0.034 NS (0.136) NS (0.498)
NS, not significant; NA, not applicable; GCB, germinal center B-cell-like; ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; IPI, international prognostic index; ECOG PS, Eastern Cooperative Oncology Group

















Figure 2 Kaplan-Meier survival curves for overall survival with log-rank test. (A) Stage, (B) international prognostic index, (C) S1PR1, and
(D) S1PR1/pSTAT3 risk category were significant prognostic factors in rituximab-treated diffuse large B-cell lymphoma patients.
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these observations, pSTAT3 expression itself is thought to
have an influence on the prognosis of DLBCLs in a more
complicated way, which remains to be further investigated.
S1PR1 signaling can be blocked by an effective inhibi-
tor, FTY720, which was developed as an immunosup-
pressant and is being used in the treatment of patients
with multiple sclerosis [20]. Moreover, other selective
S1PR1 modulators such as Syl930 have been developed
to reduce side effects including bradycardia [29]. These
molecules may be useful for functional studies to clarifyTable 4 Multivariate survival analysis of S1PR1/pSTAT3 expre
in a total cohort of rituximab-treated DLBCL patients (N = 10
Multivariate analysis with IPI
Clinicopathologic variables Category
IPI 3-5 vs. 0-2
B symptoms present vs. absent
S1PR1 positive vs. negative
Multivariate analysis with IPI, B sympto
Clinicopathologic variables Category
IPI 3-5 vs. 0-2
B symptoms present vs. absent
S1PR1/pSTAT3 risk category
high risk (S1PR1+) vs. intermediate risk (S1
high risk (S1PR1+) vs. low risk (S1PR1
DLBCL, diffuse large B-cell lymphoma; IPI, international prognostic index. *P values lthe role of S1PR1 signaling in the biology of DLBCL. In
a previous study by Liu, STAT3 was co-localized with
S1PR1 in the tumor cells of a few ABC DLBCL tissues,
and the inhibition of S1PR1 with FTY720 or S1PR1
shRNA successfully suppressed STAT3 activity and tumor
cell growth in vitro and in an in vivo murine lymphoma
model [18]. SPHK1, which catalyzes S1P production
within the cells, was more frequently expressed in B-cell
non-Hodgkin lymphomas with higher clinical grade [30].
Considering that the immunohistochemical expression of
S1PR1 was independently associated with poor clinicalssion and clinicopathologic variables for overall survival
3)
, B symptoms, and S1PR1
Univariate analysis Multivariate analysis
P* P* HR [95% CI]
0.009 0.019 2.7 [1.2-6.2]
0.014 0.180 1.7 [0.8-3.9]
0.018 0.005 3.0 [1.4-6.5]
ms, and S1PR1/pSTAT3 risk category
Univariate analysis Multivariate analysis
P* P* HR [95% CI]
0.009 0.021 2.7 [1.2-6.2]
0.014 0.208 1.6 [0.7-3.9]
0.010 0.019
PR1-/pSTAT3+) 0.024 2.7 [1.1-6.2]
-/pSTAT3-) 0.021 3.8 [1.2-11.6]
ess than 0.05 are considered significant.
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http://www.biomedcentral.com/1471-2407/14/911outcome of DLBCL patients in the present study, the S1P/
S1PR1 pathway is suspected to play a role in contributing
to the aggressive behavior of DLBCL and, in addition to
STAT3, is considered to be a promising therapeutic target
in DLBCL.
To measure the expression level of proteins in this
study, we used IHC method and graded according to the
intensities and proportions of the stained tumor cells in
DLBCL tissues. To more validate our data, a proteomic
study using spectral abundance in a shotgun study or a
more quantitative multiple reaction monitoring might
also be applicable in future studies [31,32].
Another notable finding in this study is that S1PR1 and
pSTAT3 are frequently expressed by DLBCLs primarily oc-
curring in the extranodal and UAT areas. Although UAT
has been described as a unique site of extranodal NK/T cell
lymphoma, no specific features have been recognized for
DLBCLs of the primary UAT lesion. Interestingly, a recent
study revealed that S1P/S1PR1/STAT3 signaling was an
important link between chronic intestinal inflammation
and colitis-associated cancer [33]. Considering the import-
ant role of the S1PR1/STAT3 pathway in the inflammatory
reaction and inflammation-associated carcinogenesis, this
anatomic predilection of S1PR1 and STAT3-expressing
DLBCLs suggests that the S1PR1/STAT3 pathway may be
involved in lymphomagenesis in inflammation-prone areas,
such as UAT.
Conclusions
We demonstrate here that S1PR1 is a new immunohis-
tochemical prognostic marker and that the S1PR1/
pSTAT3 risk category can be used for risk stratification
in rituximab-treated DLBCL patients. We also suggest
that the S1PR1 may be a potential therapeutic target in
a subset of DLBCLs.
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